Status:
ACTIVE_NOT_RECRUITING
Evaluation of TNF-α, IL-17A, and YKL-40 in GCF and Serum of Psoriasis Patients and Healthy Controls
Lead Sponsor:
Zhala Vatankha Sain
Conditions:
Psoriasis (PsO)
Periodontal Disease
Eligibility:
All Genders
25-65 years
Brief Summary
Background: Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the global population and is linked to immune dysregulation and systemic inflammation. Periodontitis, a chronic infla...
Detailed Description
Psoriasis and periodontitis are chronic inflammatory diseases that share key immunopathological mechanisms. Psoriasis is primarily a dermatological condition, but it also exhibits systemic inflammator...
Eligibility Criteria
Inclusion
- Age between 25 and 65 years.
- Confirmed diagnosis of chronic plaque psoriasis (for PS+G, PS+P group) by a board-certified dermatologist.
- Diagnosis of Gingivitis and Stage II or III, Grade B or C periodontitis (for P and PS+P groups) based on the 2017 World Workshop on the Classification of Periodontal Diseases and Conditions.
- At least 20 remaining teeth.
- No history of systemic conditions that could affect periodontal health, such as diabetes mellitus, autoimmune diseases, or cardiovascular diseases.
- No prior periodontal treatment within the last 6 months.
- No use of antibiotics, anti-inflammatory medications, or immunosuppressive drugs in the last 3 months.
- Non-smokers or those who have not smoked in the past year.
- Willingness to participate voluntarily and provide written informed consent.
Exclusion
- Age below 25 or above 65 years.
- Diagnosis of any systemic inflammatory disease other than psoriasis, such as rheumatoid arthritis, inflammatory bowel disease, or systemic lupus erythematosus.
- History of malignancy or chemotherapy/radiotherapy treatment.
- Use of antibiotics, corticosteroids, or immunosuppressive drugs within the last 3 months.
- Pregnant or lactating women.
- Current smokers or individuals who have smoked within the last year.
- History of substance abuse or chronic alcohol consumption.
- Presence of acute infections, including oral or systemic infections.
- Refusal to sign the informed consent form or inability to comply with the study protocol
Key Trial Info
Start Date :
November 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06897722
Start Date
November 4 2024
End Date
April 1 2025
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Akdeniz University Faculty of Dentistry, Akdeniz University Hospital
Antalya, Antalya, Turkey (Türkiye), 07070